Pilot clinical trial of blue-light blocking glasses to improve cancer patient health-related quality of life

Block Center for Integrative Cancer Treatment0 个研究点目标入组 30 人开始时间: 2017年1月13日最近更新: 2023年3月6日

适应症

试验速览

2022 Results article in https://doi.org/10.1177/20503121221100137 (added 21/02/2023)

•1. Histologically confirmed, advanced or metastatic cancer (solid tumors other than brain, esophageal or pancreatic cancer)
•2. Patients with more than one malignancy or with a prior malignancy are eligible to participate, if that other cancer is currently under control
•3. Life expectancy of 6 months or more in the judgment of the treating physician
•4. Patient must be scheduled to receive at least 3 cycles of chemotherapy, other systemic anti-cancer therapy, or ongoing active palliative care
•5. Patient may start this study at any cycle in their treatment, and any reasonable cycle length is acceptable as long as measurements can be taken before each treatment
•6. Any number of previous treatments with chemotherapy and/or other systemic targeted therapies are permitted
•7. Prior or concurrent treatment on another clinical trial is not exclusionary for participation
•8. ECOG Performance Status of 0, 1, or 2

•1. Active concomitant malignancy not currently under control
•2. Women who are pregnant, breast-feeding or planning to become pregnant during the study
•3. Less than 30 days from major surgery
•4. Less than 30 days from radiation therapy
•5. Uncontrolled/Symptomatic brain or CNS metastases
•6. Symptomatic spinal cord compression
•7. Uncontrolled psychiatric disorders that would prevent participation in the study in the judgment of the treating physician
•8. Serious co-morbidity that would interfere with the patient’s capacity to participate in the study in the judgment of the treating physician
•9. Blindness from any cause
•10. Night shift workers
•11. Melatonin supplementation

发起方

Block Center for Integrative Cancer Treatment